Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Merus stock price, quote, forecast and news

MRUS
NL0011606264
A2AKFX

Price

53.59
Today +/-
+0.21
Today %
+0.45 %
P

Merus stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Merus stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Merus stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Merus stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Merus's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Merus Stock Price History

DateMerus Price
8/23/202453.59 undefined
8/22/202453.35 undefined
8/21/202453.56 undefined
8/20/202453.71 undefined
8/19/202453.68 undefined
8/16/202451.66 undefined
8/15/202451.58 undefined
8/14/202450.56 undefined
8/13/202451.10 undefined
8/12/202451.75 undefined
8/9/202450.74 undefined
8/8/202450.01 undefined
8/7/202449.00 undefined
8/6/202449.93 undefined
8/5/202450.07 undefined
8/2/202452.10 undefined
8/1/202452.42 undefined
7/31/202453.04 undefined
7/30/202453.37 undefined
7/29/202455.23 undefined

Merus Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Merus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Merus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Merus’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Merus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Merus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Merus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Merus’s growth potential.

Merus Revenue, EBIT and net profit per share

DateMerus RevenueMerus EBITMerus Net Income
2029e900.35 M undefined0 undefined364.43 M undefined
2028e471.5 M undefined61.22 M undefined47.02 M undefined
2027e299.78 M undefined-160.23 M undefined-93 M undefined
2026e109.5 M undefined-228.47 M undefined-233.11 M undefined
2025e56.83 M undefined-232.41 M undefined-249.39 M undefined
2024e33.55 M undefined-199.73 M undefined-212.89 M undefined
202343.95 M undefined-156.55 M undefined-154.94 M undefined
202241.59 M undefined-160.04 M undefined-131.19 M undefined
202149.11 M undefined-89.98 M undefined-66.82 M undefined
202029.94 M undefined-75.88 M undefined-85.51 M undefined
201931.13 M undefined-56.86 M undefined-55.15 M undefined
201838.38 M undefined-45.74 M undefined-28.31 M undefined
201724.71 M undefined-38.64 M undefined-73.05 M undefined
20162.78 M undefined-29.19 M undefined-52.47 M undefined
20152.19 M undefined-20.66 M undefined-25.72 M undefined
20141.73 M undefined-17.02 M undefined-23.09 M undefined
2013740,000 undefined-13.15 M undefined-13.16 M undefined

Merus Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0122243831294941433356109299471900
--100.00-1,100.0058.33-18.42-6.4568.97-16.334.88-23.2669.7094.64174.3157.5391.08
-----------------
00000000000000000
-13-17-20-29-38-45-56-75-89-160-156-199-232-228-160610
--1,700.00-1,000.00-1,450.00-158.33-118.42-180.65-258.62-181.63-390.24-362.79-603.03-414.29-209.17-53.5112.95-
-13-23-25-52-73-28-55-85-66-131-154-212-249-233-9247364
-76.928.70108.0040.38-61.6496.4354.55-22.3598.4817.5637.6617.45-6.43-60.52-151.09674.47
14.2414.2414.2413.2419.222.2924.2229.2638.6444.9251.61000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Merus Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Merus is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
14.61.935.772.3220.4235.4239.8207.8410.4290.2354.38
0.20.200.21.93.42.71.76.34.12.43
0.80.50.411.90.20.200.40.61.55
00000000000
0.10.41.41.11.54.44.78.57.111.510.46
15.7337.574.6225.7243.4247.4218424.2306.4368.81
0.50.40.40.71.45.28.987.324.823.5
00008.502020.336.557.31
00000000000
0.80.60.50.40.42.92.92.82.321.8
00000000000
00.30.20.30.21.42.22.42.56.94.07
1.31.31.11.410.59.51613.232.470.286.68
174.338.676236.2252.9263.4231.2456.6376.6455.49
0.30.30.81.52.12.42.93.24.54.85.88
0.040.040.10.150.260.360.440.490.790.871.13
-32.3-49.3-68.8-112.8-190.5-259.4-314.6-400.1-466.9-598.1-753.06
000002.91.69.1-9.2-30.4-22.53
00000000000
10.5-4.330.735.867.9105.9131.3102.3316.3247.2356.34
1.32.92.62.43.43.233.113.29.84.6
0.80.71.32.23.111.214.923.22437.340.16
3.13.22.83.426.619.518.820.434.731.824.33
00000000000
2002002002000000000
5.476.98.233.133.936.746.771.978.969.09
1.10.80.50.30000000
00000000000
00.70.431.8135113.295.382.268.550.630.06
1.11.50.932.1135113.295.382.268.550.630.06
6.58.57.840.3168.1147.1132128.9140.4129.599.15
174.238.576.1236253263.3231.2456.7376.7455.49
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Merus provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Merus's financial health and stability.

Assets

Merus's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Merus must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Merus after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Merus's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-13-23-25-52-73-28-55-85-66-131-154
00000011112
000000000-10
330-1-12-21-15-1415-18-25
001285812142762561
00000000000
00000000003
-9-19-25-28-42-46-63-79-59-149-142
00000-4-2-10-7-3
0000-46-2524-1-1462-27
0000-46-20260-14510-23
00000000000
00800000000
15851558463743928258230
158605521063743928158230
0000126000000
00000000000
6-113426104-1433-3478-9356
-9.36-19.55-25.66-29.01-43.01-50.44-65.65-81.19-60.5-157.54-146.19
00000000000

Merus stock margins

The Merus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merus.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Merus's sales revenue. A higher gross margin percentage indicates that the Merus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Merus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Merus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Merus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Merus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Merus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Merus Margin History

Merus Gross marginMerus Profit marginMerus EBIT marginMerus Profit margin
2029e0 %0 %40.48 %
2028e0 %12.98 %9.97 %
2027e0 %-53.45 %-31.02 %
2026e0 %-208.65 %-212.88 %
2025e0 %-408.98 %-438.87 %
2024e0 %-595.34 %-634.56 %
20230 %-356.22 %-352.56 %
20220 %-384.8 %-315.44 %
20210 %-183.22 %-136.06 %
20200 %-253.44 %-285.6 %
20190 %-182.65 %-177.16 %
20180 %-119.18 %-73.76 %
20170 %-156.37 %-295.63 %
20160 %-1,050 %-1,887.41 %
20150 %-943.38 %-1,174.43 %
20140 %-983.82 %-1,334.68 %
20130 %-1,777.03 %-1,778.38 %

Merus Stock Sales Revenue, EBIT, Earnings per Share

The Merus earnings per share therefore indicates how much revenue Merus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Merus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Merus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Merus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Merus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Merus Revenue, EBIT and net profit per share

DateMerus Sales per ShareMerus EBIT per shareMerus Earnings per Share
2029e13.36 undefined0 undefined5.41 undefined
2028e7 undefined0 undefined0.7 undefined
2027e4.45 undefined0 undefined-1.38 undefined
2026e1.63 undefined0 undefined-3.46 undefined
2025e0.84 undefined0 undefined-3.7 undefined
2024e0.5 undefined0 undefined-3.16 undefined
20230.85 undefined-3.03 undefined-3 undefined
20220.93 undefined-3.56 undefined-2.92 undefined
20211.27 undefined-2.33 undefined-1.73 undefined
20201.02 undefined-2.59 undefined-2.92 undefined
20191.29 undefined-2.35 undefined-2.28 undefined
20181.72 undefined-2.05 undefined-1.27 undefined
20171.29 undefined-2.01 undefined-3.8 undefined
20160.21 undefined-2.2 undefined-3.96 undefined
20150.15 undefined-1.45 undefined-1.81 undefined
20140.12 undefined-1.2 undefined-1.62 undefined
20130.05 undefined-0.92 undefined-0.92 undefined

Merus business model

Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus is one of the most popular companies on Eulerpool.com.

Merus SWOT Analysis

Strengths

Merus NV has several strengths that give it a competitive advantage in the market. These strengths include:

  • Advanced technology and expertise in bispecific antibody development
  • Diverse portfolio of intellectual property rights and patents
  • Strong financial position and revenue growth
  • Experienced and knowledgeable management team
  • Strong industry partnerships and collaborations

Weaknesses

Despite its strengths, Merus NV also faces certain weaknesses that may hinder its growth and performance. These weaknesses include:

  • Dependence on a limited number of key customers for a significant portion of revenue
  • Relatively small market share compared to larger competitors
  • Potential vulnerability to changes in government regulations and healthcare policies
  • High research and development costs

Opportunities

Merus NV has several opportunities to capitalize on in the market. These opportunities include:

  • Increasing demand for targeted cancer therapies
  • Growing biopharmaceutical market globally
  • Potential for strategic partnerships and collaborations to expand product pipeline
  • Emerging markets and untapped geographical regions

Threats

However, several threats can pose challenges to Merus NV's growth and success. These threats include:

  • Intense competition in the biotechnology and biopharmaceutical industry
  • Potential for regulatory hurdles and delays in product approvals
  • Uncertainty in healthcare reimbursement landscape
  • Risk of intellectual property infringement by competitors

Merus Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Merus historical P/E ratio, EBIT, and P/S ratio.

Merus shares outstanding

The number of shares was Merus in 2023 — This indicates how many shares 51.605 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Merus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Merus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Merus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Merus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Merus.

Merus latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.78 -0.81  (-3.86 %)2024 Q2
3/31/2024-0.82 -0.59  (28.31 %)2024 Q1
12/31/2023-0.75 -1.04  (-38.21 %)2023 Q4
9/30/2023-0.75 -0.43  (42.7 %)2023 Q3
6/30/2023-0.89 -0.66  (25.98 %)2023 Q2
3/31/2023-1.04 -0.86  (17.04 %)2023 Q1
12/31/2022-0.84 -1.81  (-114.94 %)2022 Q4
9/30/2022-0.64 -0.53  (17.08 %)2022 Q3
6/30/2022-0.63 -0.13  (79.45 %)2022 Q2
3/31/2022-0.63 -0.43  (32.2 %)2022 Q1
1
2
3
4

Merus list of shareholders

%
Name
Stocks
Change
Date
7.05 % Commodore Capital LP4,747,373319,30112/31/2023
5.94 % Incyte Corp4,004,54403/25/2024
5.07 % Samlyn Capital, LLC3,412,410155,89212/31/2023
4.48 % Deerfield Management Company, L.P.3,019,901-857,03712/31/2023
4.09 % BVF Partners L.P.2,752,420012/31/2023
3.52 % RTW Investments L.P.2,373,625376,86112/31/2023
3.41 % Federated Hermes Global Investment Management Corp.2,297,700-1,339,6092/29/2024
3.19 % VR Adviser, LLC2,148,214422,00012/31/2023
2.98 % Wellington Management Company, LLP2,009,403-725,84412/31/2023
2.82 % Boxer Capital, L.L.C.1,900,000012/31/2023
1
2
3
4
5
...
10

Merus Executives and Management Board

Dr. Sven Lundberg59
Merus President, Chief Executive Officer, Executive Director (since 2019)
Compensation 5.74 M
Dr. Andrew Joe57
Merus Chief Medical Officer
Compensation 2.06 M
Mr. Peter Silverman45
Merus Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Compensation 1.97 M
Dr. Hui Liu50
Merus Chief Business Officer and Head of Merus U.S. (since 2018)
Compensation 1.96 M
Dr. Anand Mehra47
Merus Non-Executive Independent Chairman of the Board
Compensation 354,556
1
2
3

Merus Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Sema4 Holdings A Stock
Sema4 Holdings A
SupplierCustomer0,640,650,910,73-0,30-
Incyte Stock
Incyte
SupplierCustomer0,020,480,22-0,15-0,45-0,67
Betta Pharmaceuticals A Stock
Betta Pharmaceuticals A
SupplierCustomer0,02-0,770,820,69-0,05-0,55
Ono Pharmaceutical Stock
Ono Pharmaceutical
SupplierCustomer0,02-0,63-0,84-0,72-0,17-0,52
Eli Lilly Stock
Eli Lilly
SupplierCustomer-0,27-0,31-0,31-0,360,020,71
1

Most common questions regarding Merus

What values and corporate philosophy does Merus represent?

Merus NV represents values such as innovation, collaboration, and patient-centricity. With a commitment to advancing bispecific antibody therapeutics, Merus NV aims to improve patient outcomes and address unmet medical needs. The company's corporate philosophy is based on fostering scientific excellence and leveraging its core technologies to develop transformative medicines. Merus NV embraces a culture of integrity, diversity, and teamwork, driving its pursuit of novel solutions in the field of oncology. By integrating its unique approach with strategic partnerships, Merus NV strives to deliver breakthrough treatments for patients.

In which countries and regions is Merus primarily present?

Merus NV is primarily present in the Netherlands and the United States.

What significant milestones has the company Merus achieved?

Merus NV, a leading biotechnology company, has achieved several significant milestones. The company successfully initiated multiple clinical trials, including ongoing studies for its innovative bispecific antibody programs. Merus NV also secured strategic collaborations with renowned pharmaceutical companies, further validating its cutting-edge technology and expanding its market reach. In addition, Merus NV has received regulatory approvals for its investigational therapies, paving the way for potential commercialization. These achievements demonstrate the company's strong commitment to advancing its pipeline and driving growth. Merus NV's dedication to scientific excellence and continuous innovation positions it as a formidable player in the biotech industry.

What is the history and background of the company Merus?

Merus NV is a biotechnology company based in the Netherlands. Founded in 2003, the company specializes in developing innovative bispecific antibody therapeutics for the treatment of cancer. Merus NV has a unique approach to target tumor cells directly while minimizing side effects. The company has a strong pipeline of candidates, including MCLA-128, MCLA-117, and MCLA-158, targeting various types of cancers. With collaborations and partnerships with renowned pharmaceutical companies, Merus NV aims to advance the field of antibody therapeutics and make a lasting impact on patient care. Throughout its history, Merus NV has achieved significant milestones in drug discovery and clinical development, positioning itself as a key player in the biotechnology industry.

Who are the main competitors of Merus in the market?

The main competitors of Merus NV in the market include biotechnology companies such as Regeneron Pharmaceuticals, Inc., Amgen Inc., Genmab A/S, and Roche Holding AG. These companies operate in similar therapeutic areas, developing innovative antibody-based therapeutics and immuno-oncology treatments, potentially competing with Merus NV's pipeline. It is important for investors and market participants to closely monitor the competitive landscape as it can impact Merus NV's market share, product development, and financial performance.

In which industries is Merus primarily active?

Merus NV is primarily active in the biotechnology industry.

What is the business model of Merus?

The business model of Merus NV focuses on developing innovative bispecific antibody therapeutics to treat various types of cancer. By utilizing its proprietary technology platform, Merus aims to design and develop bispecific antibodies that can simultaneously target and bind to multiple cancer cell targets. This unique approach has the potential to enhance the efficacy and safety profile of cancer treatments. Merus collaborates with pharmaceutical companies to advance its pipeline candidates, while also retaining rights to develop and commercialize certain product candidates. Through its research and development efforts, Merus NV strives to provide groundbreaking solutions for patients suffering from cancer-related diseases.

What is the P/E ratio of Merus 2024?

The Merus P/E ratio is -12.99.

What is the P/S ratio of Merus 2024?

The Merus P/S ratio is 82.43.

What is the AlleAktien quality score of Merus?

The AlleAktien quality score for Merus is 6/10.

What is the revenue of Merus 2024?

The expected Merus revenue is 33.55 M USD.

How high is the profit of Merus 2024?

The expected Merus profit is -212.89 M USD.

What is the business model of Merus

Merus NV is a biotechnology company specializing in the development of bispecific antibodies for the treatment of cancer. The company's business model is based on the research, development, and commercialization of novel therapies to combat cancer. Merus NV has three main business areas and develops products in each of these categories: therapeutic products, diagnostics, and research. The company's therapeutic products utilize bispecific antibodies (Biclonics®) that combine the properties of two different antibodies, resulting in greater specificity, higher efficacy, and reduced toxicity. Merus NV is building a pipeline of bispecific antibodies targeting a variety of cancer types. Currently, the company has three products in clinical development: MeMo, MCLA-128, and MCLA-117. Merus NV collaborates closely with renowned pharmaceutical companies such as Incyte and DSM Biomedical in the development of cancer immunotherapies. In the diagnostics product line, Merus NV offers a technology platform that enables the development of diagnostic tests for therapeutic products and supports biomarker research. The company is also involved in the development of antibody imaging tools, serving an important role in toxic analysis and biomarker-driven clinical studies. Finally, Merus NV's research department supports its own development activities as well as those of external parties through collaborations and alliances. In summary, Merus NV's business model is based on the development, commercialization, and marketing of bispecific antibodies to combat cancer. With innovative solutions and technologies in the field of diagnostic tests and therapy monitoring, the company has distinct competitive advantages and can meet the demands of customers and partners. Merus NV is a leading company in the field of bispecific antibody technology and offers a diverse product pipeline to meet the demanding requirements of the entire cancer market.

What is the Merus dividend?

Merus pays a dividend of 0 USD distributed over payouts per year.

How often does Merus pay dividends?

The dividend cannot currently be calculated for Merus or the company does not pay out a dividend.

What is the Merus ISIN?

The ISIN of Merus is NL0011606264.

What is the Merus WKN?

The WKN of Merus is A2AKFX.

What is the Merus ticker?

The ticker of Merus is MRUS.

How much dividend does Merus pay?

Over the past 12 months, Merus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Merus is expected to pay a dividend of 0 USD.

What is the dividend yield of Merus?

The current dividend yield of Merus is .

When does Merus pay dividends?

Merus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Merus?

Merus paid dividends every year for the past 0 years.

What is the dividend of Merus?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Merus located?

Merus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Merus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Merus from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Merus pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Merus in the year 2023?

In the year 2023, Merus distributed 0 USD as dividends.

In which currency does Merus pay out the dividend?

The dividends of Merus are distributed in USD.

All fundamentals about Merus

Our stock analysis for Merus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.